With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

The firm’s evolving strategy to invest earlier in companies’ lifecycles could be affected by COVID-19

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing on its own or creating companies from scratch. But as the firm braces for COVID-19’s ongoing effects, it could seek out later-stage deals for awhile as the outbreak’s influence deal flow and the marketplace become clear.

Managing

Read the full 715 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE